China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price in January. But this ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Merck & Co. is facing a class action lawsuit over Gardasil sales projections. Learn how to recover losses with Levi & ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Merck Life Science opens formulation & technology centre in Turbhe, Navi Mumbai: Our Bureau, Bengaluru Tuesday, February 25, ...

With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next.

Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. These ...